Similarly, seven days after randomization, empagliflozin significantly reduced NT-proBNP levels when administered as add-on therapy for T2D people admitted for acute decompensated HF compared with the group treated conventionally with glucose-lowering agents [136]. Here, NPPB is linked to type 2 diabetes mellitus.